ストックスクリーナーアプリを入手
1.88
1.08%
0.02
アフターアワーズ：
1.88
前日終値:
$1.86
開ける：
$1.89
24時間の取引高:
43,672
Relative Volume:
0.18
時価総額：
$49.18M
収益：
-
当期純損益:
$-25.94M
株価収益率:
-1.3623
EPS:
-1.38
ネットキャッシュフロー:
$-15.79M
1週間 パフォーマンス:
-1.05%
1か月 パフォーマンス:
-5.05%
6か月 パフォーマンス:
-41.80%
1年 パフォーマンス:
+25.33%
1日の値動き範囲:
$1.84
$1.91
1週間の範囲:
$1.73
$1.94
52週間の値動き範囲:
$1.24
$5.99
MAIA Biotechnology Inc Stock (MAIA) Company Profile
名前
MAIA Biotechnology Inc
セクター
電話
312 416 8592
住所
444 West Lake Street, Suite 1700, Chicago
MAIA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.88 | 49.18M | 0 | -25.94M | -15.79M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
MAIA Biotechnology Inc (MAIA) 最新ニュース
MAIA Biotechnology, BeiGene announce clinical supply agreement - The Cancer Letter
Geode Capital Management LLC Grows Position in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) - Defense World
MAIA Biotech to Present THIO Cancer Treatment Pipeline at Biotech Showcase 2025 - StockTitan
MAIA Biotechnology Shares Rise After Supply Agreement With BeiGene - MarketWatch
MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications - BioSpace
MAIA Biotech partners with BeiGene for cancer trials - Investing.com
MAIA Biotechnology Directors Show Strong Confidence with $573K Personal Investment in Private Placement - StockTitan
MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings - Business Wire
Big Moves at MAIA Biotechnology! Insider Buying and Market Insights - Clinique Bio
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas - Business Wire
Investing Insights: MAIA Biotechnology’s Promising Moves - Clinique Bio
Stan Smith Acquires 25,000 Shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Stock - MarketBeat
Maia Biotechnology director Stan Smith acquires $46,800 in stock - Investing.com India
Maia Biotechnology director Stan Smith acquires $46,800 in stock By Investing.com - Investing.com South Africa
Maia Biotechnology director Ramiro Guerrero buys $99,998 in stock - Investing.com
Maia Biotechnology director Ramiro Guerrero buys $99,998 in stock By Investing.com - Investing.com UK
MAIA Biotechnology, Inc. announced that it expects to receive $0.949785 million in funding - Marketscreener.com
MAIA Biotechnology announces $950,000 private placement - MSN
MAIA Biotechnology Secures $950K Private Placement to Advance THIO Clinical Trials - StockTitan
MAIA Biotech expands phase 2 trial for lung cancer treatment By Investing.com - Investing.com South Africa
MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer - XM
MAIA Biotech expands phase 2 trial for lung cancer treatment - Investing.com
MAIA Biotech Expands Cancer Trial with Regeneron, Reports Promising NSCLC Results - StockTitan
Diamond Equity Forecasts MAIA Biotechnology Q1 Earnings - Defense World
Analysts Set Expectations for MAIA Biotechnology Q1 Earnings - MarketBeat
MAIA Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
THIO Combo Shows Enduring Activity in Advanced Non–Small Cell Lung Cancer - Cancer Network
MAIA Biotechnology Inc (MAIA): A New Perspective - Stocks Register
MAIA Biotechnology Reveals Promising Phase 2 Trial Results - TipRanks
MAIAMAIA Biotechnology, Inc. Latest Stock News & Market Updates - StockTitan
MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement - BioSpace
MAIA Director Backs Cancer Drug Developer with $225,900 Stock Purchase, Shows Insider Confidence - StockTitan
MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - Yahoo Finance
Maia Biotechnology director Stan Smith buys shares worth $250,999 - Investing.com
Maia Biotechnology director Stan Smith buys shares worth $250,999 By Investing.com - Investing.com Canada
Insider Buying: MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Acquires 22,133 Shares of Stock - MarketBeat
Director Cristian Luput Acquires 22,133 Shares of MAIA Biotechno - GuruFocus.com
Director Ramiro Guerrero Acquires 88,534 Shares of MAIA Biotechn - GuruFocus.com
Maia Biotechnology director Steven Chaouki buys $55,553 in shares By Investing.com - Investing.com Australia
Maia Biotechnology director Steven Chaouki buys $55,553 in shares - Investing.com
Maia Biotechnology director Luput acquires shares worth $55,553 By Investing.com - Investing.com Nigeria
Maia Biotechnology director Luput acquires shares worth $55,553 - Investing.com
Cosmo Metals Secures $500,000 for Strategic Expansion - MSN
Antipa Minerals Expands Share Offering on ASX - MSN
WAM Alternative Assets Expands ASX Securities Offering - MSN
Argent BioPharma Issues New Shares Amidst Strategic Growth - MSN
MAIA Biotechnology Announces $2.44 Million Private Placement - Business Wire
MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Down 3.4%Here's What Happened - MarketBeat
MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Down 3.4% – Time to Sell? - Defense World
Alterity Therapeutics Prepares for 2024 Annual General Meeting - MSN
Li Bang International announces pricing of initial public offering - MSN
MAIA Biotechnology Inc (MAIA) 財務データ
収益
当期純利益
現金流量
EPS
3.95%
2.39%
大文字化:
|
ボリューム (24 時間):